|
|
Commercializing on Protein Kinase InhibitorsPublished by: BioSeeker Group AB Published: Feb. 10, 2004 - 480 Pages Table of Contents Executive Summary Methodology Introduction Major Players New Players Leaving Players Other Players Highly Cited Patents Protein kinase C Inhibitors VEGF/VEGFr/FLT Inhibitors HER/EGF/EGFr Inhibitors PDGF/PDGFr Inhibitors MAP/MEK/P38/ERK/Rho Kinase Inhibitors PI3 Inhibitors CDK Inhibitors Conclusion Appendix A - Selected Company Profiles AbstractNo analysis is better than the accuracy of the information that it is based upon. That is why BioSeeker Group has chosen to found "Commercializing on Protein Kinase Inhibitors" on the intellectual property of this promising and vast field. This report will guide you through the complicated and heterogenous field of protein kinase inhibition. You will find out which companies are setting the agenda. You will understand the changes in strategy that have been undertaken during the last decade. Some companies have completely left the field, some have re-allocated the resources to alternative types of protein kinase inhibitors, and some have chosen to enter this highly competitive field despite the furious battle going on. Whether you want to partner up with a major player of protein kinase inhibition, inlicense innovative intellectual property, or get a feeling of your competitive situation, "Commercializing on Protein Kinase Inhibitors" will save you hundreds of hours and show you which way to proceed ahead for the years to come. Protein kinases (PK) are a broad range of proteins with different properties and functions in a cell. Phosphorylation of target molecules as a step in signal transduction or enzyme regulation is the common feature of kinases. Generally one can divide them into 2 main groups; serine/threonine and tyrosine kinases. The consequences of this seemingly simple activity are staggering; cell growth, differentiation and proliferation, i.e., virtually all aspects of cell life in one way or another depend on PK activity. Furthermore, abnormal PK activity has been related to a host of disorders, ranging from relatively non life-threatening diseases such as psoriasis to extremely virulent diseases such as glioblastoma (brain cancer). In view of the apparent link between PK-related cellular activities and a wide variety of human disorders, a great deal of effort is being expended in an attempt to identify ways to modulate PK activity. BioSeeker has compiled almost 2500 patents in the field of protein kinase inhibition and selected the most commercially interesting for structure and analysis. The patents are presented both companywise and sorted by the actual target. In the first section we have grouped the companies into four categories - major players, new players, leaving players, and other players. For each company we present patent data grouped according to the different protein kinase targets, as well as an analysis of the company´s activities. The second section discusses the most highly cited patents, which the applicants are, and also exciting information regarding the patents and applicants citing these key patents. The third section focuses on some of the major protein kinases. Companies have been sorted according to their patent activity for each of these kinases. In depth information of these targets are also provided, as well as references to breakthrough historical articles and patents. Finally, an extensive appendix is provided with company profiles for all the major players in protein kinase inhibition. This will help you get quick and reliable background information about these companies as well as contact details ready to use. A selection of the companies featured in this report: Abbott, Agouron, Albany, Alcon, Allergan, American Cyanamid, Amgen, AstraZeneca, Aventis, Bayer, Boehringer Ingelheim, BristolMyersSquibb, Canji, Cellegy, Cell Pathways, Celltech, Cephalon, Ceptyr, Chiron, CV Therapeutics, DuPont Pharm, Eli Lilly, Genentech, GlaxoSmithKline, GPC Biotech, Icos, ISIS Pharmaceuticals, Kirin, Merck, Novartis, Pfizer, Pharmacia, Roche, Sankyo, Sanofi Scios, Senju, Shearwater, Synthelabo, Schering AG, Sugen, Takeda, Vertex, and many more. A selection of the targets featured in this report: Tyrosine kinase inhibitors, serine/threonine kinase inhibitors, VEGFr inhibitors, EGFr/HER inhibitors, PDGFr inhibitors, MAP/MEK/P38 kinase inhibitors, CDK inhibitors, protein kinase C (PKC) inhibitors, SRC kinase inhibitors, Rho kinase inhibitors, Raf kinase inhibitors, glycogen synthase kinase inhibitors, phosphatidylinositol-3 (PI3) kinase inhibitors, thymidine kinase inhibitors, JNK inhibitors, and many more.
|
|
|||
|
About MarketResearch.com
|
||||